Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Tissues that did not meet qualitative standards of adequate PPIB were excluded from further analysis
Participants received once-weekly injections of retatrutide at either the 9mg or 12mg dose, or a placebo, over 68 weeks
In the SYSUCC-002 study, endocrine therapy combined with trastuzumab demonstrates efficacy not inferior to that of chemotherapy combined with trastuzumab, while also reducing the toxic side effects associated with chemotherapy and improving patient compliance
Yano W, Inoue N, Ito S, Itou T, Yasumura M, Yoshinaka Y, et al
In Phase 3 TRIUMPH-1 data, nausea was reported in 28.6% of participants taking 4 mg, 38.4% taking 9 mg, and 42.4% taking 12 mg, compared with 14.8% of participants receiving placebo
US$ 29.61
US$ 22.72
US$ 28.64
